AO Foundation   Report issue

Foundation Phase 3
Founded: Davos Switzerland (1958)

Organization Overview

First Clinical Trial
2011
NCT01257828
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

AO North America | AOSpine North America | AOSpine North America Research Network

Active Ingredients

Drugs in Phase 3 Trials (2)

riluzole (rilutek) (2 trials)

tranexamic acid (cyklokapron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Marrow Diseases (Phase 3)

Congenital Abnormalities (Phase 3)

Spinal Cord Diseases (Phase 3)

Spinal Cord Injuries (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2